RECRUITINGOBSERVATIONAL
A Clinical Cohort Registry Study on Primary PCI for Acute Myocardial Infarction at Zhongshan Hospital
About This Trial
This study is a registry-based cohort investigation, prospectively enrolling patients who were diagnosed with acute myocardial infarction and underwent primary percutaneous coronary intervention (PCI) at Zhongshan Hospital, Fudan University, between January 1, 2009, and December 31, 2028. Baseline clinical characteristics, procedural details, laboratory results, and medication records will be systematically collected and documented. The clinical follow-up will encompass both in-hospital monitoring and post-discharge surveillance extending up to two years after the procedure.
Who May Be Eligible (Plain English)
Who May Qualify:
- Elevated or decreasing levels of cardiac troponin T, with at least one measurement exceeding 0.014 ng/mL;
- Presence of at least one of the following: symptoms of myocardial ischemia; newly onset ischemic changes on ECG; pathological Q wave; imaging evidence of new loss of viable myocardium or regional wall motion abnormalities consistent with ischemia; coronary angiography confirming the presence of a thrombus;
- Undergoing primary PCI;
- Voluntary willing to sign a consent form to participate in the study.
Who Should NOT Join This Trial:
- Inability to complete emergent PCI (e.g., due to intraoperative complications or inability to tolerate the procedure).
- Prior administration of thrombolytic therapy before PCI.
- Diagnosis of type 2 or type 3 myocardial infarction.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Elevated or decreasing levels of cardiac troponin T, with at least one measurement exceeding 0.014 ng/mL;
* Presence of at least one of the following: symptoms of myocardial ischemia; newly onset ischemic changes on ECG; pathological Q wave; imaging evidence of new loss of viable myocardium or regional wall motion abnormalities consistent with ischemia; coronary angiography confirming the presence of a thrombus;
* Undergoing primary PCI;
* Voluntary informed consent to participate in the study.
Exclusion Criteria:
* Inability to complete emergent PCI (e.g., due to intraoperative complications or inability to tolerate the procedure).
* Prior administration of thrombolytic therapy before PCI.
* Diagnosis of type 2 or type 3 myocardial infarction.
Treatments Being Tested
OTHER
Collection of baseline characteristics
Collection of baseline clinical characteristics, procedural details, laboratory results, and medication records
Locations (1)
Shanghai Zhongshan Hospital
Shanghai, China